AI assistant
IMPEDIMED LIMITED — Capital/Financing Update 2020
Apr 28, 2020
65135_rns_2020-04-28_f4ac05e9-9d5d-4d5f-be8f-3e52ee6c6978.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [230 x 55] intentionally omitted <==
29 April 2020
ASX ANNOUNCEMENT
CHANGE IN EXERCISE PRICE OF OPTIONS
Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) ( ImpediMed or the Company ) announced a non-renounceable accelerated entitlement offer of 13 new shares ( New Shares ) for every 10 shares at a price of $0.0375 per New Share on 2 April 2020 ( Entitlement Offer ).
ImpediMed advises that, as a consequence of the Entitlement Offer, the exercise prices of various unquoted options over fully paid ordinary shares in the capital of ImpediMed ( Options ) are to be recalculated based on the formula set out in the rules of the Company’s 2014 Employee Incentive Plan adopted by a resolution of directors on 18 September 2014 ( EIP ).
The revised exercise prices of the EIP Options will change on 6 May 2020 and are set out in the table below.
| Options (#) | Current exercise price (A$) | New exercise price (A$) |
|---|---|---|
| 195,000450,000498,000 | 0.04000.11000.1333 | 0.03540.1054 |
| 0.1286 | ||
| 8,001,362 | 0.1500 | 0.1454 |
| 230,000 | 0.1700 | 0.1654 |
| 70,000 | 0.2283 | 0.2236 |
| 100,000 | 0.2300 | 0.2254 |
| 578,000 | 0.5183 | 0.5136 |
| 53,500 | 0.6383 | 0.6336 |
| 306,000 | 0.6783 | 0.6736 |
| 4,234,000 | 0.6883 | 0.6836 |
| 120,000 | 0.7383 | 0.7336 |
| 4,974,000 | 0.8133 | 0.8086 |
| 672,000 | 0.8683 | 0.8636 |
| 375,000 | 0.9283 | 0.9236 |
1
ImpediMed Limited ASX Announcement
==> picture [159 x 38] intentionally omitted <==
| Options (#) | Current exercise price (A$) | New exercise price (A$) |
|---|---|---|
| 512,500 | 0.9983 | 0.9936 |
| 200,000 | 1.0283 | 1.0236 |
| 50,000 | 1.0483 | 1.0436 |
| 200,000 | 1.3183 | 1.3136 |
| 1,207,000 | 1.4583 | 1.4536 |
| 566,500 | 1.4683 | 1.4636 |
| 518,000 | 1.6583 | 1.6536 |
Authorised for release by the Board of Directors of ImpediMed Limited.
Contact Details
Investor Relations Contact: Mike Bassett, ImpediMed T: +61 407 431 432 E: [email protected]
Media Contact:
Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy.
ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.
For more information, visit www.impedimed.com.
2
ImpediMed Limited ASX Announcement